azacitidine has been researched along with Minimal Disease, Residual in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (60.71) | 24.3611 |
| 2020's | 11 (39.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chyla, B; Dail, M; DiNardo, CD; Döhner, H; Fracchiolla, NS; Garcia, JS; Illes, A; Jang, JH; Jonas, BA; Ozcan, M; Potluri, J; Pratz, KW; Pullarkat, V; Recher, C; Schuh, AC; Thirman, MJ; Vorobyev, V; Yamamoto, K; Yeh, SP; Zhou, Y | 1 |
| Beach, CL; Döhner, H; Dombret, H; La Torre, I; Menezes, DL; Ossenkoppele, G; Porkka, K; Ravandi, F; Risueño, A; Roboz, GJ; Schuh, AC; Skikne, B; Thol, F; Voso, MT; Wei, AH; Zhong, J | 1 |
| Cenfra, N; Cimino, G; Divona, M; La Barbera, EO; Lapietra, G; Mecarocci, S; Perrone, S; Voso, MT | 1 |
| Abbott, D; Bosma, G; Gutman, JA; Jordan, C; Minhajuddin, M; Pollyea, DA; Winters, AC | 1 |
| Beach, CL; Chan, ET; Döhner, H; Dombret, H; Lopes de Menezes, D; Montesinos, P; Porkka, K; Ravandi, F; Risueño, A; Roboz, GJ; Sandhu, I; See, WL; Skikne, B; Thakurta, A; Thol, FR; Ugidos, M; Wei, AH | 1 |
| Abbott, D; Amaya, M; Brecl, C; Dell-Martin, J; Falco, A; Gutman, JA; Ho, P; Jordan, CT; Kent, A; McMahon, C; Minhajuddin, M; O'Brien, K; Ondracek, O; Pei, S; Pollyea, DA; Schowinsky, J; Smith, C; Sohalski, C; Stevens, B; Taylor, E; Tobin, J; Winters, A; Zhou, K | 1 |
| Cao, Y; Chen, X; Feng, S; Guo, W; Han, M; He, Y; Jiang, E; Liu, J; Liu, X; Ma, Q; Pang, A; Wang, M; Wei, J; Yang, D; Zhai, W; Zhang, R; Zheng, Y | 1 |
| Abbott, D; Boggs, C; Chase, S; Ewalt, MD; Gutman, JA; Halsema, K; Jordan, CT; Kaiser, J; Lyle, L; Nakic, M; Pollyea, DA; Purev, E; Rana, V; Rosser, J; Schowinsky, JT; Schuster, S; Siegele, B; Smith, C; Stevens, BM; Tobin, J; Winters, AC | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Barwe, SP; Gopalakrishnapillai, A; Kolb, EA; Quagliano, A | 1 |
| Alemdar, MS; Atas, U; Undar, L; Yucel, OK | 1 |
| Chojecki, A | 1 |
| Borthakur, G; Cortes, J; Daver, N; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, HM; Ohanian, M; Oran, B; Pemmaraju, N; Ragon, BK; Ravandi, F | 1 |
| Advani, AS; Bixby, D; DeAngelo, DJ; Erba, HP; Faderl, S; Fathi, AT; Ho, PA; Jillella, A; Kovacsovics, TJ; Lancet, JE; Levy, MY; O'Meara, MM; Ravandi, F; Stein, AS; Stein, EM; Voellinger, J; Walter, RB | 1 |
| Basak, G; Boguradzki, P; Chmarzyńska-Mróz, E; Drozd-Sokołowska, J; Dwilewicz-Trojaczek, J; Jędrzejczak, W; Karakulska-Prystupiuk, E; Kulikowska, A; Paluszewska, M; Stefaniak, A; Waszczuk-Gajda, A | 1 |
| Baldus, CD; Bochtler, T; Borkmann, C; Bornhäuser, M; Bug, G; Dührsen, U; Ehninger, G; Fransecky, L; Götze, KS; Groth, C; Hänel, M; Herbst, R; Krämer, A; Kramer, M; Kubasch, AS; Mende, M; Middeke, JM; Mütherig, A; Noppeney, R; Oelschlägel, U; Platzbecker, U; Röllig, C; Schetelig, J; Schubert, A; Serve, H; Sockel, K; Stelljes, M; Stölzel, F; Thiede, C; von Bonin, M; Wolf, D | 1 |
| Akahane, D; Azuma, K; Fujimoto, H; Furuya, N; Katagiri, S; Kobayashi, C; Nakamura, N; Ohyashiki, JH; Ohyashiki, K; Suguro, T; Umezu, T | 1 |
| Estey, EH; Percival, MM | 1 |
| Chang, C; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Q; Zhang, X; Zhang, Z; Zhou, L | 1 |
| Inoue, A; Kawakami, C; Takitani, K; Tamai, H | 1 |
| Cao, L; Du, XJ; Fang, F; Feng, X; Hu, SY; Li, YH; Li, YP; Li, ZH; Lu, J; Ni, J; Pan, J; Su, GH; Sun, LC; Tao, YF; Wang, J; Wang, NN; Xiao, PF; Xu, LX; Xu, YY; Zhao, H; Zhao, WL | 1 |
| Ginat, R; Maman, S; Meshel, T; Naftali, O; Sagi-Assif, O; Witz, IP | 1 |
| Brown, YD; Cortes, JE; Kantarjian, HM; Maiti, A | 1 |
| Bornhäuser, M; Ehninger, G; Kiani, A; Platzbecker, U; Thiede, C; Wermke, M | 1 |
| Akbulak, R; Atanackovic, D; Bartels, BM; Bartels, K; Bokemeyer, C; Brümmendorf, TH; Cao, Y; Gontarewicz, A; Gordic, M; Hildebrandt, Y; Kobold, S; Kröger, N; Lajmi, N; Luetkens, T; Meyer, S; Schafhausen, P; Stasche, T; Uhlich, F | 1 |
| Bornhäuser, M; Ehninger, G; Kiani, A; Platzbecker, U; Radke, J; Schaich, M; Sockel, K; Thiede, C; Wermke, M | 1 |
| Bornhäuser, M; Ehninger, G; Graehlert, X; Kiani, A; Klut, IM; Knoth, H; Mohr, B; Oelschlaegel, U; Platzbecker, U; Radke, J; Röllig, C; Schetelig, J; Seltmann, F; Thiede, C; Wermke, M | 1 |
| Chan, KW; Lockhart, S; McDonald, L; Rytting, M | 1 |
2 review(s) available for azacitidine and Minimal Disease, Residual
| Article | Year |
|---|---|
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
9 trial(s) available for azacitidine and Minimal Disease, Residual
| Article | Year |
|---|---|
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis; Remission Induction; Sulfonamides | 2022 |
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Topics: Antimetabolites; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis; Recurrence; Remission Induction | 2022 |
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Topics: Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Prognosis; Protein-Tyrosine Kinases; Recurrence; Remission Induction | 2022 |
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual | 2023 |
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Decitabine; Disease-Free Survival; Epigenesis, Genetic; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Translocation, Genetic; Vidarabine | 2017 |
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzodiazepines; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Pyrroles; Sialic Acid Binding Ig-like Lectin 3; Survival Rate | 2018 |
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Drug Administration Schedule; Female; Germany; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Nucleophosmin; Progression-Free Survival; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Time Factors | 2018 |
Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Azacitidine; Biomarkers; Bone Marrow; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chimerism; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Recurrence; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
17 other study(ies) available for azacitidine and Minimal Disease, Residual
| Article | Year |
|---|---|
Azacitidine to Consolidate and Deepen the Therapeutic Response Achieved by Intensive Induction Treatment in a Young Patient Affected by NPM1mut-AML Who Has Become Ineligible for High-Dose Consolidation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Remission Induction | 2022 |
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
Topics: Adult; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies; Sulfonamides | 2022 |
Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia.
Topics: Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies; Transplantation, Homologous | 2023 |
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Female; Follow-Up Studies; Genetic Testing; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Sulfonamides; Treatment Outcome | 2019 |
CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia.
Topics: Azacitidine; Bone Marrow; Child; Humans; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Tetraspanin 28; Tumor Microenvironment | 2020 |
Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid Leukemia.
Topics: Adult; Azacitidine; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; Remission Induction | 2020 |
Minimal Residual Disease in Acute Myelogenous Leukemia Is Predictive, Unless You Are Over Age 60 and Treated with Decitabine.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual | 2021 |
Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplasm, Residual; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Young Adult | 2018 |
Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Topics: Adult; Allografts; Azacitidine; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Neoplasm, Residual | 2019 |
Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Topics: Abnormal Karyotype; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytogenetic Analysis; Decitabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Risk Assessment; Survival Rate | 2013 |
Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Transplantation, Homologous | 2014 |
Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients.
Topics: Acute Disease; Azacitidine; Cell Line, Tumor; Child; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Neoplasm, Residual; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; U937 Cells | 2014 |
PHOX2B is a suppressor of neuroblastoma metastasis.
Topics: Animals; Azacitidine; Biomarkers, Tumor; DNA Methylation; Homeodomain Proteins; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Neuroblastoma; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Transcription Factors | 2016 |
Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Proto-Oncogene Proteins c-abl; Recurrence | 2010 |
Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunity, Humoral; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines | 2010 |
Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Recurrence; Treatment Outcome | 2011 |
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy.
Topics: Azacitidine; Benzamides; Child, Preschool; Chromosome Aberrations; Decitabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation | 2012 |